宫颈癌骨盆骨髓保护放疗的临床结局:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入17项随机对照试验共1297例宫颈癌患者,评估在同步放化疗基础上增加骨盆骨髓保护(BMS)对临床结局的影响。结果显示BMS显著降低≥3级和≥2级血液学毒性,并减少化疗中断(完成不足5周期顺铂)的频率,未发现胃肠道或泌尿生殖毒性增加。但数据不足以验证对生存和疾病控制的影响。
要点
- BMS显著降低≥3级血液学毒性(OR 0.39;95%CI 0.28-0.55;p<0.001)和≥2级血液学毒性(OR 0.29;95%CI 0.18-0.46;p<0.001)。
- BMS组化疗中断(接受不足5周期顺铂)显著减少(OR 0.44;95%CI 0.24-0.81;p=0.016)。
- 未发现胃肠道或泌尿生殖毒性增加的证据;数据不足以验证对生存和疾病控制的影响。
核心结论
- 在宫颈癌患者根治性同步放化疗中增加BMS可降低血液学毒性和同步化疗中断的频率。
- 数据不足以验证BMS对生存和疾病控制的影响。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、Web of Science核心合集、Google Scholar、Sinomed、CNKI和万方数据库2010年1月1日至2023年10月31日发表的中英文文献。
- 纳入17项前瞻性随机试验共1297例接受根治性或术后同步放化疗的宫颈癌患者。
- 多数为单中心试验(n=1268),在中国进行(n=1128);多数试验采用基于CT的解剖学BMS(n=1076)。
- 根治性设置试验n=655,术后设置试验n=582,其余试验包含两种设置。
- 使用Cochrane协作网偏倚风险工具评估偏倚风险,采用随机效应模型进行Meta分析。
主要发现
- 12项研究报告了≥3级(n=782)和≥2级(n=754)血液学不良事件数据,BMS组≥3级毒性OR 0.39(95%CI 0.28-0.55;p<0.001),≥2级毒性OR 0.29(95%CI 0.18-0.46;p<0.001),均显著降低。
- 7项研究(n=635)报告了化疗中断(定义为接受不足5周期顺铂)数据,BMS组化疗中断显著减少(OR 0.44;95%CI 0.24-0.81;p=0.016)。
- 未发现胃肠道或泌尿生殖毒性增加的证据。
- 未发现显著异质性迹象。
- 4项研究评为高偏倚风险,排除这些研究的敏感性分析对主要结局提供了可比的结果。
关键数值与推荐
- BMS组≥3级血液学毒性OR 0.39(95%CI 0.28-0.55;p<0.001),≥2级血液学毒性OR 0.29(95%CI 0.18-0.46;p<0.001)。
- BMS组化疗中断(接受不足5周期顺铂)OR 0.44(95%CI 0.24-0.81;p=0.016)。
临床怎么用
- 原文结论指出,在宫颈癌患者根治性同步放化疗中增加BMS可降低血液学毒性和同步化疗中断的频率。
- 原文结论指出,数据不足以验证BMS对生存和疾病控制的影响。
局限性
- 主要局限性包括研究间BMS方法学的异质性。
- 宫颈癌最主要受影响人群的代表性低。
- 数据不足以评估生存结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concurrent chemoradiotherapy (CRT) is the standard treatment for locally advanced cervical cancer. We investigated how additional bone marrow sparing (BMS) affects the clinical outcomes. METHODS: We queried MEDLINE, Embase, Web of Science Core Collection, Google Scholar, Sinomed, CNKI, and Wanfang databases for articles published in English or Chinese between 2010/01/01 and 2023/10/31. Full-text manuscripts of prospective, randomised trials on BMS in cervical cancer patients treated with definitive or postoperative CRT were included. Risk of bias (RoB) was assessed using Cochrane Collaboration's RoB tool. Random-effects models were used for the meta-analysis. RESULTS: A total of 17 trials encompassing 1297 patients were included. The majority were single-centre trials (n = 1268) performed in China (n = 1128). Most trials used CT-based anatomical BMS (n = 1076). There was a comparable representation of trials in the definitive (n = 655) and postoperative (n = 582) settings, and the remaining trials included both.Twelve studies reported data on G ≥ 3 (n = 782) and G ≥ 2 (n = 754) haematologic adverse events. Both G ≥ 3 (OR 0.39; 95 % CI 0.28-0.55; p < 0.001) and G ≥ 2 (OR 0.29; 95 % CI 0.18-0.46; p < 0.001) toxicity were significantly lowered, favouring BMS. Seven studies (n = 635) reported data on chemotherapy interruptions, defined as receiving less than five cycles of cisplatin, which were significantly less frequent in patients treated with BMS (OR 0.44; 95 % CI 0.24-0.81; p = 0.016). There was no evidence of increased gastrointestinal or genitourinary toxicity.There were no signs of significant heterogeneity. Four studies were assessed as high RoB; sensitivity analyses excluding these provided comparable results for main outcomes. The main limitations include heterogeneity in BMS methodology between studies, low representation of populations most affected by cervical cancer, and insufficient data to assess survival outcomes. CONCLUSIONS: The addition of BMS to definitive CRT in cervical cancer patients decreases hematologic toxicity and the frequency of interruptions in concurrent chemotherapy. However, data are insufficient to verify the impact on survival and disease control.
引用
- Miszczyk M, Wu T, Kuna K, et al. Clinical outcomes of pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis of randomised controlled trials. Clin Transl Radiat Oncol. 2024. PMID: 38946805. doi:10.1016/j.ctro.2024.100801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。